Fresenius Medical Care, the world’s leading provider of dialysis products and services, has agreed to issue bonds with an aggregate principal amount of USD 1 billion.
Solid revenue growth continued; Significant net income growth; Exceptionally positive free cash flow development; Financial targets for FY2020 confirmed inclusive of anticipated COVID-19 effects
Fresenius Medical Care, the world’s leading provider of dialysis products and services, will hold its Annual General Meeting (AGM) on August 27, 2020 as a virtual event.
Fresenius Medical Care North America intends to open more than 100 new transitional care units (TCUs) this year.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is aware that patient data from some of the company’s dialysis centers in Serbia has been published by unauthorized persons.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today successfully placed bonds in two tranches with an aggregate volume of €1.25 billion.
9% revenue increase supported by growth in all regions; Positive earnings growth despite negative impact from COVID-19 pandemic; Solid cash-flow development; Financial targets for FY2020 confirmed
Fresenius Medical Care, the world’s leading provider of dialysis products and services, has released an advisory calling for clinical care principles on access to be upheld for patients with advanced chronic kidney disease if a surge in COVID-19 infections overwhelms the available supply of facilities, caregivers and ventilators.
